Skyrizi
NDC Package 0074-7036-04

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Skyrizi is ™ is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Marketed by Abbvie Inc., this product is identified by NDC 0074-7036 and is authorized under FDA application BLA761105.

Identification & Billing

NDC Package Code
0074-7036-04
Package Description
4 CARTON in 1 CARTON / 1 KIT in 1 CARTON * 1 mL in 1 SYRINGE, GLASS (0074-7032-01)
Product Code
0074-7036
11-Digit Billing Format
00074703604
RxNorm Crosswalk
  • RxCUI: 2166136 - risankizumab-rzaa 75 MG in 0.83 mL Prefilled Syringe
  • RxCUI: 2166136 - 0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe
  • RxCUI: 2166136 - risankizumab-rzaa 75 MG per 0.83 ML Prefilled Syringe
  • RxCUI: 2166137 - {2 (0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe) } Pack
  • RxCUI: 2166137 - risankizumab-rzaa 75 MG in 0.83 mL (2) Prefilled Syringe Pack

Clinical Specifications

Proprietary Name
Skyrizi
Dosage Form
-
Usage Information
SKYRIZI™ is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Regulatory & Marketing

Labeler Name
Abbvie Inc.
FDA Application #
BLA761105
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
03-22-2023
End Marketing Date
06-21-2024
Listing Expiration
06-21-2024
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0074-7036-04 identifies a specific commercial package of 4 carton in 1 carton / 1 kit in 1 carton * 1 ml in 1 syringe, glass (0074-7032-01) of Skyrizi, labeled by Abbvie Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Abbvie Inc. on March 22, 2023. The current certification is valid through June 21, 2024.

How is this Abbvie Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074703604. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0074-7036-04
11-Digit CMS (5-4-2)
00074-7036-04

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.